Neoadjuvant Therapy Combined With Radical Surgery for the Treatment of Small Cell Lung Cancer (SCLC) in II and IIIA Stage
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to compare the effects of neoadjuvant with radical surgery
on the prognosis of patients with stage II and IIIA small cell lung cancer (SCLC). The
primary endpoint of this study is to observe 5-year survival, disease-free survival (DFS),
and overall survival (OS) in patients. Secondary efficacy indicators include recurrence rate,
surgical complications, resection rate, quality of life (QoL), and exploration biomarker
(tumor tissue).
This is a two-arm, open, multicentral clinical study designed to assess the disease-free
survival (DFS) and overall survival (OS) of neoadjuvant chemotherapy plus radical surgery for
stage II and IIIA small cell lung cancer (SCLC). About 300 patients will be enrolled in the
study and randomly divided into two groups of 150 individuals. The neoadjuvant with radical
surgery group received 2 to 4 cycles of neoadjuvant treatment with etoposide plus
cisplatin/carboplatin before receiving radical surgery, followed by 2 to 4 cycles of adjuvant
chemotherapy (etoposide with cisplatin/carboplatin) plus radiotherapy. Patients in the
control group are planned to receive 4 to 6 courses of etoposide plus cisplatin/carboplatin
for chemotherapy and radiotherapy.